About PHER-O2
PHER-O2 contains perfluorodecalin, purified water and an emulsifier that allows the product to be administered intravenously. Perfluorodecalin is a biologically inert substance that is not metabolized by the body but rather, is excreted from the body through normal respiration.
Perfluorocarbons are currently approved for use in the US in eye surgery and medical imaging; they are approved outside of the US for other medical indications.
Sanguine plans to accelerate the development of PHER-02 through strategic and targeted joint ventures, partnerships and licenses with industry partners.
Successor to Fluosol-DA
PHER-O2 is a reformulated version of Fluosol-DA, which was developed under the management of Dr. Drees and is the only FDA-approved intravenous perfluorocarbon emulsion. Fluosol was also granted marketing approval in Canada, the UK, Germany, Australia and New Zealand. As a newer and better product, we believe that PHER-02 will benefit from the success of its predecessor and enable the Company to pursue a fast track through the development and FDA approval process.
News & Updates
